Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
Tingting Jiang,
Guan Wang,
Yao Liu,
Lu Feng,
Meng Wang,
Jie Liu,
Yi Chen,
Liang Ouyang
Affiliations
Tingting Jiang
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China
Guan Wang
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China
Yao Liu
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China
Lu Feng
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China
Meng Wang
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China
Jie Liu
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China
Yi Chen
State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China; Corresponding authors. Tel./fax: +86 28 85503817.
Liang Ouyang
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China; Corresponding authors. Tel./fax: +86 28 85503817.
